Reporting on market developments concerning AbbVie Revenue Rises on Strength in Immunology, Neuroscience. Industry analysts and investors are monitoring the operational, strategic,...

Bristol Myers Squibb is defending its clinical pipeline after a patient death in an autoimmune trial, reassuring investors over its broader immunology strategy.

Bristol Myers Squibb has raised its annual financial outlook following stronger-than-expected quarterly revenue, driven by robust uptake in its growth portfolio.

Eli Lilly posted significant revenue gains driven by unprecedented global demand for its blockbuster treatments Mounjaro and Zepbound, solidifying its leadership in the metabolic therapeutics market.

Biogen swung to a quarterly net loss even as top-line revenue advanced, driven by new product launches and heavy pipeline realignment expenses.

Novartis boosted its full-year earnings guidance on resilient core portfolio momentum, even as late-stage clinical trial hurdles pressured bottom-line results.

Healthcare equities navigate margin scrutiny, Medicare Advantage reimbursement adjustments, and strategic biopharma acquisitions as investors reposition for sector resilience.

Healthcare equities face shifting sentiment as institutional investors weigh drug pricing scrutiny, rising clinical costs, and M&A opportunities across the sector.